News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 04, 2015, 09:31 ET Sorrento kondigt een positief resultaat aan van het TRIBECA™-registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is verheugd met de bekendmaking van het positieve resultaat van de onlangs geanalyseerde...


May 04, 2015, 09:00 ET Sorrento Announces Positive TRIBECA™ Registrational Study Results

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive results from recently analyzed pharmacokinetic (PK) data from its...


May 01, 2015, 13:13 ET Sorrento Acquires South American Rights To Cynviloq™

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a late-stage clinical oncology company developing new treatments...


Apr 30, 2015, 16:32 ET Sorrento Announces the Appointments of David H. Deming to the Board of Directors and Mark W. Durand as Chief Financial Officer

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...


Apr 13, 2015, 09:00 ET Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...


Mar 30, 2015, 09:00 ET Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today the appointment of George K. Ng to the position of Executive Vice President & Chief...


Mar 17, 2015, 07:20 ET NantWorks et Sorrento annoncent une deuxième collaboration mondiale complète sur la découverte et le développement de nouvelles immunothérapies anticancéreuses

- NantCell acquiert les droits exclusifs d'anticorps comprenant les produits CAR-TNK™ et les inhibiteurs des points de contrôle PD-1 et...


Mar 17, 2015, 07:14 ET NantWorks en Sorrento kondigen tweede brede wereldwijde samenwerking aan in de ontdekking en ontwikkeling van nieuwe immunotherapieën tegen kanker

- NantCell zal exclusieve rechten verwerven op antilichamen waaronder CAR-TNK™ Producten en de checkpointremmers PD-1 en PD-L1...


Mar 16, 2015, 13:56 ET NantWorks und Sorrento kündigen ihre zweite, umfassende, weltweite Kooperation bei der Entdeckung und Entwicklung neuartiger Immunotherapien gegen Krebs an

- NantCell erwirbt die exklusiven Rechte an Antikörpern, wie den CAR-TNK™ Produkten und den Checkpoint-Inhibitoren PD-1 und PD-L1...


Mar 16, 2015, 09:00 ET NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

 NantWorks, Inc. and Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that they have entered into a...


Feb 23, 2015, 09:00 ET Sorrento to Present at Cowen and Company's 35th Annual Health Care Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), an oncology company developing new treatments for cancer and associated...


Feb 05, 2015, 09:00 ET Sorrento to Present at the 17th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...


Feb 02, 2015, 09:00 ET Sorrento Announces Retention of Glen Sato to Provide Strategic Support

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


Aug 26, 2014, 08:45 ET Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Aug 18, 2014, 07:45 ET Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Aug 08, 2014, 17:00 ET Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Apr 07, 2014, 15:58 ET Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...


Apr 04, 2014, 09:43 ET Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Apr 04, 2014, 06:00 ET Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new...


Mar 31, 2014, 21:31 ET Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...